Showing 3561-3570 of 5773 results for "".
- Alcon Champions Access to Eye Care with Opening of Children’s Vision Center in Fort Worth, Texashttps://modernod.com/news/alcon-champions-access-to-eye-care-with-opening-of-childrens-vision-center-in-fort-worth-texas/2481337/Alcon announced the grand opening of the Alcon Children’s Vision Center. Located at 8376 Mojave Trail in Fort Worth, Texas, the center is a first-of-its-kind partnership between the Alcon Foundation and the Fort Worth Independent School District (FWISD). The center offers comprehensive
- Bausch + Lomb Introduces Enhanced PreserVision AREDS 2 Formula Mini Soft Gels with OCUSorbhttps://modernod.com/news/bausch-lomb-introduces-enhanced-preservision-areds-2-formula-mini-soft-gels-with-ocusorb/2481335/Bausch + Lomb announced the US introduction of PreserVision AREDS 2 Formula mini soft gels with OCUSorb. This product is the only AREDS 2 eye vitamin with the OCUSorb formulation. Offering a proprietary composition of lutein and zeaxanthin, Bausch + Lomb said OCUSorb has
- Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officerhttps://modernod.com/news/alimera-sciences-appoints-industry-veteran-russell-l-skibsted-as-chief-financial-officer/2481331/Alimera Sciences announced the appointment of Russell L. Skibsted as Senior Vice President and Chief Financial Officer (CFO), effective January 9, 2023. “We are extremely excited to have someone of Russell’s caliber join us here at Alimera,” Rick Eiswirth, P
- EyeCare Partners Expands Footprint in Oklahoma with Retinal Associates of Oklahomahttps://modernod.com/news/eyecare-partners-expands-footprint-in-oklahoma-with-retinal-associates-of-oklahoma/2481328/EyeCare Partners (ECP) announced that it has expanded its presence in Oklahoma through a partnership with Retinal Associates of Oklahoma (RAO). Terms of the deal were not disclosed. The ECP network welcomes Darin R. Haivala, MD, and Rob
- Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy FT-001 for the Treatment of Leber Congenital Amaurosis-2https://modernod.com/news/frontera-therapeutics-doses-first-patient-in-phase-1-clinical-trial-for-gene-therapy-ft-001-for-the-treatment-of-leber-congenital-amaurosis-2/2481327/Frontera Therapeutics announced that it has dosed the first patient in a phase 1 clinical trial of its lead gene therapy program, FT-001, for the treatment of Leber Congenital Amaurosis-2, a severe inherited retinal disease related to a mutation in the RPE65 gene. FT-001 is administered by a
- Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Eye Care Divisionhttps://modernod.com/news/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-viatris-eye-care-division-1/2481326/Viatris announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7. Former Oyster Point Pharma CEO, Jeffrey Nau, PhD, MMS, will lead the new di
- Shamir Glacier Plus Metaform on Transitions Signature GEN 8 Brown and Grey Now Availablehttps://modernod.com/news/shamir-glacier-plus-metaform-on-transitions-signature-gen-8-brown-and-grey-now-available/2481325/Shamir announced the launch of Shamir Glacier Plus Metaform, a new lens coating that is designed to remove compromises experienced with other lenses. According to Shamir, features of the coating include: Up to 20% thinner & lighter t
- Alcon Introduces Reusable Toric Lens with Launch of TOTAL30 for Astigmatismhttps://modernod.com/news/alcon-introduces-reusable-toric-lens-with-launch-of-total30-for-astigmatism/2481324/Alcon announced plans to launch TOTAL30 for Astigmatism, which the company calls the first-and-only reusable contact lens with water gradient material for astigmatic contact lens wearers. Using Alcon’s proprietary water gradient material, first introduced with DAILIES TOTAL1&
- Oculis Completes Patient Recruitment for Stage 1 of Phase 3 DIAMOND Study Evaluating the Efficacy and Safety of OCS-01 in DMEhttps://modernod.com/news/oculis-completes-patient-recruitment-for-stage-1-of-phase-3-diamond-study-evaluating-the-efficacy-and-safety-of-ocs-01-in-dme/2481323/Oculis announced the completion of enrollment for stage 1 of its phase 3 DIAMOND (DIAbetic Macular edema patients ON a Drop) study evaluating the efficacy and safety of OCS-01 in patients with diabetic macular edema (DME). At the end of 2021, Oculis launched its 2-stage,
- Apellis Appoints Caroline Baumal, MD, as Chief Medical Officerhttps://modernod.com/news/apellis-appoints-caroline-baumal-md-as-chief-medical-officer/2481321/Apellis Pharmaceuticals announced that retina specialist Caroline Baumal, MD, has joined Apellis as chief medical officer. Dr. Baumal replaces Federico Grossi, MD, PhD, who plans to remain at Apellis until February 28, 2023 to help with the transition and preparations for the potential launc